Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study.

In a secondary analysis of the phase III RESORCE trial in patients with HCC, median overall survival and time‐to‐progression tended to be longer in patients with higher regorafenib exposure during the first treatment cycle; however, after correction for several covariates, it did not reach statistical significance. 12 To our knowledge, this trial is the only available evidence on a possible exposure – response relationship for regorafenib; therefore, more research is necessary on this point.

also in 111,027 other papers